Mirum Pharmaceuticals (MIRM) Downgraded by Zacks Investment Research to Sell

Mirum Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Mirum Pharmaceuticals Downgraded by Zacks Investment Research on 10/15/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Mirum Pharmaceuticals (MIRM) Downgraded by Zacks Investment Research to Sell